Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)

被引：3

作者：

Yu, Evan Y. ^{[1
,2
]}

Piulats, Josep M. ^{[3
]}

Gravis, Gwenaelle ^{[4
]}

Fong, Peter C. C. ^{[5
,6
]}

Todenhoefer, Tilman ^{[7
]}

Laguerre, Brigitte ^{[8
]}

Arranz, Jose A. ^{[9
]}

Oudard, Stephane ^{[10
]}

Massard, Christophe ^{[11
,12
]}

Heinzelbecker, Julia ^{[13
,14
]}

Nordquist, Luke T. ^{[15
]}

Carles, Joan ^{[16
]}

Kolinsky, Michael P. ^{[17
,18
]}

Augustin, Marinela ^{[19
]}

Gurney, Howard ^{[20
]}

Tafreshi, Ali ^{[21
]}

Li, Xin Tong ^{[22
]}

Qiu, Ping ^{[22
]}

Poehlein, Christian H. ^{[22
]}

Schloss, Charles

de Bono, Johann S. ^{[23
,24
]}

机构：

[1] Univ Washington, Seattle, WA USA

[2] Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Catalan Inst Oncol, Barcelona, Spain

[4] Inst Paoli Calmettes, Marseille, France

[5] Auckland City Hosp, Auckland, New Zealand

[6] Univ Auckland, Auckland, New Zealand

[7] Studienpraxis Urol, Nurtingen, Germany

[8] Ctr Eugene Marquis, Rennes, France

[9] Gen Univ Hosp Gregorio Maranon, Madrid, Spain

[10] Univ Paris, Hop Europeen Georges Pompidou, Paris, France

[11] Gustave Roussy, Canc Campus, Villejuif, France

[12] Paris Saclay Univ, Villejuif, France

[13] Saarland Univ, Med Ctr, Homburg, Germany

[14] Saarland Univ, Fac Med, Homburg, Germany

[15] GU Res Network Urol Canc Ctr, Omaha, NE USA

[16] Vall Hebron Inst Oncol, Barcelona, Spain

[17] Cross Canc Inst, Edmonton, AB, Canada

[18] Univ Alberta, Edmonton, AB, Canada

[19] Paracelsus Med Univ, Nurnberg, Germany

[20] Macquarie Univ, Sydney, Australia

[21] Univ Wollongong, Wollongong, NSW, Australia

[22] Merck & Co Inc, Rahway, NJ USA

[23] Inst Canc Res, London, England

[24] Royal Marsden, London, England

来源：

EUROPEAN UROLOGY | 2023年 / 83卷 / 03期

关键词：

D O I：

10.1016/j.eururo.2022.11.025

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E87 / E87

页数：1

共 50 条

[41] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Massard, Christophe
Retz, Margitta
Hammerer, Peter
Quevedo, Fernando
Fong, Peter C. C.
Berry, William R.
Gurney, Howard
Piulats, Josep M.
Joshua, Anthony
Linch, Mark David
Kolinsky, Michael
Romano, Emanuela
Sridhar, Srikala S.
Conter, Henry Jacob
Augustin, Marinela
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[42] Phase II Cohort Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) with new Cohorts Phase Ib/II Study of Combination Therapies with Pembrolizumab (MK-3475) in Patients with mCRPC (KEYNOTE-365) - Study AP 94/16 of the AUO
Rexer, H.
Retz, M.
Hammerer, P.
UROLOGE, 2022, 61 (01): : 107 - 108
[43] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Kolinsky, Michael Paul
Gravis, Gwenaelle
Mourey, Loic
Piulats, Josep M.
Sridhar, Srikala S.
Romano, Emanuela
Berry, William R.
Gurney, Howard
Retz, Margitta
Appleman, Leonard Joseph
Boegemann, Martin
De Bono, Johann S.
Joshua, Anthony M.
Emmenegger, Urban
Conter, Henry Jacob
Laguerre, Brigitte
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[44] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Berry, William R.
Fong, Peter C. C.
Piulats, Josep M.
Appleman, Leonard Joseph
Conter, Henry Jacob
Feyerabend, Susan
Shore, Neal D.
Gravis, Gwenaelle
Laguerre, Brigitte
Gurney, Howard
Retz, Margitta
Romano, Emanuela
Mourey, Loic
De Bono, Johann S.
Kam, Audrey E.
Emmenegger, Urban
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[45] Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
Graff, Julie N.
Hoimes, Christopher J.
Gerritsen, Winald R.
Vaishampayan, Ulka N.
Elliott, Tony
Hwang, Clara
ten Tije, Albert J.
Omlin, Aurelius
McDermott, Raymond S.
Fradet, Yves
Tagawa, Scott T.
Kilari, Deepak
Ferrario, Cristiano
Uemura, Hiroji
Jones, Robert J.
Fukasawa, Satoshi
Peer, Avivit
Niu, Cuizhen
Poehlein, Christian H.
Qiu, Ping
Suttner, Leah
de Wit, Ronald
Schloss, Charles
de Bono, Johann S.
Antonarakis, Emmanuel S.
PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
[46] A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA plus metastatic castration-resistant prostate cancer
Zang, Peter D.
Blanchard, Suzette
Martirosyan, Hripsime
Adkins, Lauren
Dhapola, Gaurav
Shishido, Stephanie
Young, Cari
Karam, Hala
Stiller, Tracey
D'Apuzzo, Massimo
Kuhn, Peter
Forman, Stephen J.
Priceman, Saul
Dorff, Tanya B.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Phase Ib/II-Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) Phase Ib/II-Study of Pembrolizumab (MK-3475) Combination Therapies in Patients with mCRPC (KEYNOTE-365) - Study AP 94/16 of the AUO
Rexer, H.
Wuelfing, C.
Retz, M.
UROLOGE, 2018, 57 (01): : 120 - 121
[48] Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
Petrylak, Daniel P.
Ratta, Raffaele
Matsubara, Nobuaki
Korbenfeld, Ernesto Pablo
Gafanov, Rustem
Mourey, Loic
Todenhofer, Tilman
Gurney, Howard
Kramer, Gero
Bergman, Andre M.
Zalewski, Pawel
De Santis, Maria
Armstrong, Andrew J.
Gerritsen, Winald R.
Pachynski, Russell Kent
Byun, Seok-Soo
Li, Xin Tong
Schloss, Charles
Poehlein, Christian Heinrich
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[49] KEYNOTE-199: Phase 2 nonrandomized study of pembrolizumab in patients with PD-L1+and PD-L1-metastatic castration-resistant prostate cancer
de Bono, Johann
Piulats, Josep
Gross-Goupil, Marine
Goh, Jeffrey
Ojamaa, Kristiina
Hoimes, Christopher
Vaishampayan, Ulka
Berger, Raanan
Sezer, Ahmet
De Wit, Ronald
Drake, Charles
Wu, Haiyan
Poehlein, Christian
Antonarakis, Emmanuel S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[50] Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study
Yu, Evan
Park, Se Hoon
Huang, Yi-Hsiu
Bennamoun, Mostefa
Xu, Lu
Kim, Jeri
Antonarakis, Emmanuel
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

← 1 2 3 4 5 →